Thymosin-α1 for Recurrent Implantation Failure
Recruiting
Phase 2
Phase 3
Interventional Study
Recurrent Implantation Faliure
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 40
- Sex
- Female
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 136 (estimated)
- Sponsor
- Fakih IVF Fertility Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. -Women 18-40 years
2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos
3. \- Normal parental karyotypes
4. \- Normal uterine cavity on imaging
5. \- Negative antiphospholipid panel
6. \- Thyroid and prolactin controlled within local reference standards
Excl…
Contacts